BRAF V600K Mutation Present clinical trials at UC Davis
1 research study open to eligible people
A Study of the Experimental Combination of Dabrafenib, Trametinib, and Navitoclax For BRAF Mutant Melanoma or Solid Tumors
open to eligible people ages 18 years and up
This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that have spread to other parts of the body or cannot be removed by surgery. Dabrafenib, trametinib, and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations